Abstract：【Objective】 To investigate the curative effect of Shugan Jieyu capsule combined with clomipramine in the treatment of depression. 【Methods】 A total of 96 patients with depression who were admitted to our hospital from October 2016 to October 2017 were divided into the control group and the experimental group according to random number table method. There were 48 patients in the control group and 48 patients in the experimental group. Patients in the control group were treated with clomipramine tablets at conventional dose, while patients in the experimental group were treated with Shugan Jieyu capsules combined with low-dose of clomipramine tablets. Both groups of patients were treated for 8 weeks. The Hamilton Depression Self-rating Scale (HAMD), and Ability of Daily Living Scale (ADL) were observed before and after treatment. 【Results】 The HAMD scores of the control group and the experimental group before treatment were (27.41±2.73) points and (28.19±2.58) points, respectively. After treatment, the HAMD score of the control group was 18.35±2.49 and the score of the experimental group was 9.82±2.16 , which showed lower than before treatment. The differences were statistically significant (t=3.266, P=0.002<0.05). The incidence of total adverse reactions in the control group was 29.17% (5/48) while the incidence of total adverse reactions in the experimental group was 10.42% (14/49). The difference between the two groups was statistically significant (χ2=5.315, P=0.021<0.05). The ADL scores of the control group and the experimental group were 41.23±22.25 and 42.68±23.09, respectively. After treatment, the HAMD scores of the experimental group and the control group were 62.83±19.14 and 53.47±21.97, respectively,. which were higher than before treatment. The difference was statistically significant (t=-2.226, P=0.028<0.05). 【Conclusion】 Shuganjieyu Capsules combined with clomipramine have a good effect in the treatment of depression, which significantly improves the clinical symptoms of depression in patients, reduces the adverse reactions during treatment, and promotes the daily living ability of patients.
2019, Vol. 36 
